Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Mazyar Shadman , Jeff Porter Sharman , Moshe Y. Levy , Ryan Porter , Syed Farhan Zafar , John M. Burke , Arvind Chaudhry , Benjamin Bruce Freeman , Jamal Ghazi Misleh , Habte Aragaw Yimer , Jennifer L. Cultrera , Troy H. Guthrie , Ed Kingsley , Subramanya S. Rao , Dih-Yih Chen , Aileen Cohen , Shibao Feng , Jane Huang , Ian Flinn
Background: Many patients (pts) with B-cell malignancies require continuous treatment with Bruton tyrosine kinase inhibitors (BTKi). Adverse events (AEs) are a common reason for ibrutinib (ibr) or acalabrutinib (acala) discontinuation. Early data from BGB-3111-215 showed zanubrutinib (zanu) was well tolerated in pts with B-cell malignancies intolerant to ibr or acala. We report preliminary results with a median follow-up of 4.2 mo. Methods: Pts meeting protocol criteria for intolerance to ibr, acala or both (without documented progressive disease) were given zanu monotherapy (160 mg twice daily or 320 mg once daily). Recurrence of AEs that led to intolerance of prior BTKi and additional safety measures were assessed based on the Common Terminology Criteria for AEs v5.0. Investigators determined responses using disease status at study entry as baseline. Results: As of November 1, 2020 (cutoff), 44 pts (n=34 chronic lymphocytic leukemia/small lymphocytic lymphoma, n=6 Waldenström macroglobulinemia, n=2 mantle cell lymphoma, n=2 marginal zone lymphoma) were enrolled, received ≥1 dose of zanu, and analyzed for safety. Median age was 70.5 y (range, 49-91); median duration of treatment was 4.2 mo (range, 0.1-12.6). Median number of prior regimens was 2 (range, 1-12). Regarding prior BTKi, 39 pts received ibr only, 4 received ibr and acala, and 1 received acala only. The median number of ibr- or acala-intolerant AEs per pt was 2 (range, 1-5). 83% of ibr and 78% of acala intolerant events did not reccur on zanu; Table. At data cutoff, 43 pts remained on treatment; 1 withdrew consent due to zanu-unrelated grade 3 syncope. Overall, 34 pts (77.3%) reported any AE; most commonly reported AEs were myalgia (n=9; 20.5%), contusion (n=8; 18.2%), dizziness (n=7; 15.9%), fatigue (n=7; 15.9%), and cough (n=5; 11.4%). Grade ≥3 AEs were reported in 6 pts (13.6%), serious AEs in 1 pt (2.3%, febrile neutropenia and salmonella infection), AEs requiring dose interruptions in 6 pts (13.6%), and AEs leading to dose reduction in 2 pts (4.5%). No AEs led to zanu discontinuation. No deaths were reported. All efficacy evaluable pts (26/26 [100%]) maintained (10 [38.5%]) or achieved deepening (16 [61.5%]) of their response. Conclusions: Zanu provides an additional treatment option after intolerance to other BTKi, demonstrating tolerability and sustained or improved efficacy. Updated results will be presented. Recurrence and Severity Change of AEs Leading to Ibr or Acala Intolerance. Clinical trial information: NCT04116437
AEs leading to ibr and acala intolerance, N | Recurrence on zanu, n (%) | Severity change of reccurrence on zanu, n (%) | |||
---|---|---|---|---|---|
No | Yes | Recurred at lower severity | Recurred at same severity | ||
Ibr | 87 | 72 (82.8) | 15 (17.2) | 13 (14.9) | 2 (2.3) |
Acala | 9 | 7 (77.8) | 2 (22.2) | 1 (11.1) | 1 (11.1) |
Note: Multiple events of the same preferred term for a pt are counted once for the event per the worst grade experienced before and after enrollment.
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2020 ASCO Virtual Scientific Program
First Author: Ian Flinn
2023 ASCO Annual Meeting
First Author: Susana N. Banerjee
2023 ASCO Annual Meeting
First Author: Zhen Zeng
2023 ASCO Annual Meeting
First Author: Gregory J. Riely